| dc.contributor.author | Palmieri, C | en_US |
| dc.contributor.author | Caley, MP | en_US |
| dc.contributor.author | Purshouse, K | en_US |
| dc.contributor.author | Fonseca, A-V | en_US |
| dc.contributor.author | Rodriguez-Teja, M | en_US |
| dc.contributor.author | Kogianni, G | en_US |
| dc.contributor.author | Woodley, L | en_US |
| dc.contributor.author | Odendaal, J | en_US |
| dc.contributor.author | Elliott, K | en_US |
| dc.contributor.author | Waxman, J | en_US |
| dc.contributor.author | Sturge, J | en_US |
| dc.date.accessioned | 2016-01-15T09:49:39Z | |
| dc.date.issued | 2013-01-15 | en_US |
| dc.identifier.issn | 0007-0920 | en_US |
| dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/10711 | |
| dc.description.sponsorship | We thank the patients who participated in this study; Professor Gerry Thomas and the Imperial College Healthcare NHS Trust, Human Biomaterials Resource Centre (Tissue Bank); Professor Clare M Isacke (Institute of Cancer Research, London) for Endo180 antibodies; Dr Richard Harvey (Department of Medical Oncology, Imperial College Healthcare NHS Trust) for CA 15-3 antigen measurement. The Division of Cancer at Imperial College London, Imperial College Healthcare NHS Trust is an Experimental Cancer Medicine Centre (ECMC) supported by funds from Cancer Research UK and the Department of Health (C37/A7283) and forms part of Imperial Cancer Research UK Centre (C42671/A12196). CP is recipient of a CRUK Clinician Scientist award. JW is The Flow Foundation Professor of Oncology at Imperial College London. MPC and GK were supported by donations from Tony and Rita Gallagher and Imperial College NHS Healthcare Trust Special Trustees (to JW and JS). MPC was funded by The Rosetrees Trust (Grant JS16/M59; to JW and JS). A-VF was funded by Fundação para a Ciência e Tecnologia fellowship (project supervisor: JS) and Imperial College NHS Healthcare Special Trustees (to JW and JS). MR-T was funded by the Association of International Cancer Research (Grant 08-0803 to JS). | en_US |
| dc.format.extent | 163 - 169 | en_US |
| dc.relation.ispartof | BRITISH JOURNAL OF CANCER | en_US |
| dc.rights | The final publication is available at Nature Publishing Group via http://dx.doi.org/10.1038/bjc.2012.540 | |
| dc.subject | bisphosphonates | en_US |
| dc.subject | bone metastasis | en_US |
| dc.subject | breast cancer | en_US |
| dc.subject | collagen receptor | en_US |
| dc.subject | diagnostic marker | en_US |
| dc.subject | plasma marker | en_US |
| dc.title | Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer | en_US |
| dc.type | Article | |
| dc.identifier.doi | 10.1038/bjc.2012.540 | en_US |
| pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000314800600022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
| pubs.issue | 1 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published | en_US |
| pubs.volume | 108 | en_US |
